MoonLake Immunotherapeutics
MLTX
33 hedge funds and large institutions have $396M invested in MoonLake Immunotherapeutics in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
38% more funds holding
Funds holding: 24 → 33 (+9)
36% more capital invested
Capital invested by funds: $291M → $396M (+$105M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.96% less ownership
Funds ownership: 99.8% → 96.84% (-3%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$7.79M |
| 2 |
Axa
Paris,
France
|
+$3.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.78M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.34M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.64M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.6M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$2.33M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.49M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$416K |
MLTX Hedge Fund Activity: Q4 2022 in Review
33 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q4 2022, worth a combined $396M — up 36% from $291M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new MLTX positions and 4 closed out — a net gain of 10 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $7.79M. The largest seller was Fidelity Investments, cutting an estimated $5.64M.
- 33 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q4 2022, up from 24 in Q3 2022.
- Funds reported $396M of MoonLake Immunotherapeutics stock for Q4 2022, up 36% quarter-over-quarter.
- 14 funds opened new MoonLake Immunotherapeutics positions in Q4 2022 and 4 closed out, a net change of +10 holders.
- The largest MoonLake Immunotherapeutics buyer in Q4 2022 was Polar Capital Holdings, an estimated $7.79M added.
- The largest MoonLake Immunotherapeutics seller in Q4 2022 was Fidelity Investments, an estimated $5.64M sold.
Based on aggregated 13F filings for Q4 2022.